Azome Therapeutics

Executive Summary

Azome Therapeutics is a privately held biotech company founded in 2017 and headquartered in San Diego, California. The company is focused on developing selective antagonists of the NLRP3 inflammasome, a critical mediator of sterile inflammation implicated in a broad spectrum of diseases. These include acute lung injury, Acute Respiratory Distress Syndrome (ARDS), bronchopulmonary dysplasia, systemic sepsis, acute liver and kidney injury, and pneumonia. By targeting the NLRP3 pathway, Azome aims to address significant unmet medical needs in inflammatory and autoimmune conditions where current therapies are limited or ineffective. The company's drug discovery platform leverages structure-based design and medicinal chemistry to generate orally bioavailable small molecules with high selectivity and potency against NLRP3.

Upcoming Catalysts (preview)

• Q3 2026Completion of IND-enabling studies and potential IND filing25% success
• Q1 2027Presentation of preclinical proof-of-concept data at a major conference30% success
• Q2 2026Series A financing or strategic partnership to advance lead candidate20% success